AZD1152 in patients with Advanced Solid Malignancies-Study 3

Study identifier:D1531C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a continuous 7-day Intravenous Infusion in Patients With Advanced Solid Malignancies

Medical condition

Solid tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1152

Sex

All

Actual Enrollment

45

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2006
Primary Completion Date: -
Study Completion Date: 01 Jul 2007

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria